{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:02:20Z","timestamp":1791468140808,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.htct.2026.108542","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:27:30Z","timestamp":1791466050000},"page":"108542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are quality of life data reported in clinical trials evaluating CAR T cells in hematologic malignancies?"],"prefix":"10.1016","volume":"48","author":[{"given":"Julie","family":"Bouaziz-Bohbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles A.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-8092","authenticated-orcid":false,"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.htct.2026.108542_bib0001","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PPO.0000000000000401","article-title":"Patient-reported outcomes in integrative oncology: bridging clinical care with research","volume":"25","author":"Lopez","year":"2019","journal-title":"Cancer J"},{"issue":"3","key":"10.1016\/j.htct.2026.108542_bib0002","doi-asserted-by":"crossref","DOI":"10.4081\/hpr.2013.e27","article-title":"Quality of life in chronic disease patients","volume":"1","author":"Megari","year":"2013","journal-title":"Health Psychol Res"},{"issue":"9","key":"10.1016\/j.htct.2026.108542_bib0003","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.3390\/ijerph18094428","article-title":"Dimensions used in instruments for QALY calculation: a systematic review","volume":"18","author":"Tour\u00e9","year":"2021","journal-title":"Int J Env. Res Public Health"},{"issue":"21","key":"10.1016\/j.htct.2026.108542_bib0004","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.htct.2026.108542_bib0005","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1182\/bloodadvances.2022008106","article-title":"Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL","volume":"6","author":"Abramson","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.htct.2026.108542_bib0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.htct.2026.108542_bib0014","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40273-014-0136-z","article-title":"Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010","volume":"32","author":"Wisl\u00f8ff","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.htct.2026.108542_bib0015","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"6846","key":"10.1016\/j.htct.2026.108542_bib0018","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: new outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.htct.2026.108542_bib0019","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood.V106.11.750.750","article-title":"Development of a measure of health-related quality of life for non-Hodgkin\u2019s lymphoma clinical research: the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)","volume":"106","author":"Cella","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2026.108542_bib0021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","article-title":"The PedsQL: measurement model for the pediatric quality of life inventory","volume":"37","author":"Varni","year":"1999","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.htct.2026.108542_bib0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2141.1999.01206.x","article-title":"Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life","volume":"104","author":"Stead","year":"1999","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.htct.2026.108542_bib0030","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.jval.2021.06.010","article-title":"Development of the multiple myeloma symptom and impact questionnaire: a new patient-reported outcome instrument to assess symptom and impacts in patients with multiple myeloma","volume":"24","author":"Gries","year":"2021","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.htct.2026.108542_bib0031","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1037\/a0027310","article-title":"Development and psychometric evaluation of the Personal Growth Initiative Scale\u2013II","volume":"59","author":"Robitschek","year":"2012","journal-title":"Journal of Counseling Psychology"},{"issue":"26","key":"10.1016\/j.htct.2026.108542_bib0006","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.htct.2026.108542_bib0007","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.htct.2026.108542_bib0008","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.htct.2026.108542_bib0009","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000524","article-title":"Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future","volume":"5","author":"Heine","year":"2021","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.htct.2026.108542_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transpl."},{"key":"10.1016\/j.htct.2026.108542_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2021.100304","article-title":"Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials","volume":"30","author":"Raymakers","year":"2021","journal-title":"J Cancer Policy"},{"issue":"3","key":"10.1016\/j.htct.2026.108542_bib0012","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.23.00377","article-title":"Importance of low- and moderate-grade adverse events in patients' Treatment experience and treatment discontinuation: an analysis of the E1912 trial","volume":"42","author":"O'Connell","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.htct.2026.108542_bib0017","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cam4.3664","article-title":"Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel","volume":"10","author":"Hoogland","year":"2021","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.htct.2026.108542_bib0022","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","article-title":"Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma","volume":"5","author":"Patrick","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.htct.2026.108542_bib0023","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/bjh.18677","article-title":"Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy","volume":"201","author":"Wang","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.htct.2026.108542_bib0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transpl."},{"issue":"4","key":"10.1016\/j.htct.2026.108542_bib0024","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.htct.2026.108542_bib0026","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12874-018-0649-9","article-title":"Self-reported and routinely collected electronic healthcare resource-use data for trial-based economic evaluations: the current state of play in England and considerations for the future","volume":"19","author":"Franklin","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"10.1016\/j.htct.2026.108542_bib0025","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s11136-015-0937-3","article-title":"Equivalence of electronic and paper-based patient-reported outcome measures","volume":"24","author":"Campbell","year":"2015","journal-title":"Qual Life Res"},{"issue":"12","key":"10.1016\/j.htct.2026.108542_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.htct.2026.108542_bib0028","first-page":"473","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transpl. Cell Ther"},{"issue":"3","key":"10.1016\/j.htct.2026.108542_bib0029","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.34557","article-title":"Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy","volume":"129","author":"Dhawale","year":"2023","journal-title":"Cancer"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926022893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137926022893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:27:33Z","timestamp":1791466053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137926022893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2531137926022893"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2026.108542","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are quality of life data reported in clinical trials evaluating CAR T cells in hematologic malignancies?","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2026.108542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}],"article-number":"108542"}}